Class / Patent application number | Description | Number of patent applications / Date published |
514322000 | Plural ring nitrogens in the polycyclo ring system | 75 |
20080214614 | CYTOSKELETAL ACTIVE RHO KINASE INHIBITOR COMPOUNDS, COMPOSITION AND USE - The present invention is directed to synthetic cytoskeletal active compounds that are inhibitors of rho-associated protein kinase. The present invention is also directed to pharmaceutical compositions comprising such compounds and a pharmaceutically acceptable carrier. The invention is additionally directed to a method of preventing or treating diseases or conditions associated with cytoskeletal reorganization. In one embodiment of the invention, the method treats increased intraocular pressure, such as primary open-angle glaucoma. The method comprises administering to a subject a therapeutically effective amount of a cytoskeletal active compound of Formula I or Formula II, wherein said amount is effective to influence the actomyosin interactions, for example by leading to cellular relaxation and alterations in cell-substratum adhesions. | 09-04-2008 |
20080255195 | Compounds Which Have Activity at M1 Receptor and Their Uses in Medicine - Compounds of formula (I) and salts are provided: | 10-16-2008 |
20080262040 | Chemical Compounds - The invention is directed to novel indazole carboxamide derivatives. Specifically, the invention is directed to compounds according to formula (I): | 10-23-2008 |
20080269290 | Indoles - The present invention is concerned with novel indol-2-yl-carbonyl-piperidin-benzoimidazolon and indol-2-yl-carbonyl-piperidin-benzoxazolon derivatives as V1 | 10-30-2008 |
20080293770 | Compounds Which Have Activity at M1 Receptor and Their Uses In Medicine - Compounds of formula (I) and salts are provided: | 11-27-2008 |
20080293771 | AZACYCLYLBENZAMIDE DERIVATIVES AS HISTAMINE-3 ANTAGONISTS - The present invention provides a compound of formula I and the use thereof for the treatment of a central nervous system disorder related to or affected by the histamine-3 receptor | 11-27-2008 |
20080300276 | Heterocyclic Carboxylic Acide Amide Derivatives - The invention relates to new heterocyclic carboxylic acid amide derivatives of formula (I)—wherein the meaning of X is hydrogen or halogen atom, hydroxy, cyano, C | 12-04-2008 |
20080306112 | Benzimidazolones Which Have Activity at M1 Receptor - Compounds of formula (I) and salts are provided: | 12-11-2008 |
20090005417 | Substituted Indazolyl Sulfonamide and 2,3-Dihydro-Indolyl Sulfonamide Compounds, their Preparation and Use in Medicaments - The present invention relates to substituted indazolyl sulfonamide and 2,3-dihydroindolyl sulfonamide compounds of general formula I, a process for their preparation, medicaments comprising said substituted indazolyl sulfonamide and 2,3-dihydro-indolyl sulfonamide compounds as well as the use of said substituted indazolyl sulfonamide and 2,3-dihydro-indolyl sulfonamide compounds for the preparation of medicaments, which are particularly suitable for the prophylaxis and/or treatment of disorders or diseases that are at least partially mediated via 5-HT | 01-01-2009 |
20090012123 | Protective Agent for Retinal Neuronal Cell Comprising Indazole Derivative as Active Ingredient - As a result of intensive studies for the purpose of finding a new medicinal use of an indazole derivative, it was found that an indazole derivative inhibits glutamate-induced retinal neuronal cell death in rat fetal retinal neuronal cells, in other words, the indazole derivative acts directly on the retinal neuronal cells and exhibits an effect of protecting retinal neuronal cells. Accordingly, the indazole derivative is useful for the prevention or treatment of an eye disease associated with retinal neuronal cell damage or retinal damage. | 01-08-2009 |
20090048300 | Heterocyclic Compounds - The present invention relates to compounds which are inhibitors of histone deacetylase. More particularly, the present invention relates to heterocyclic compounds and methods for their preparation. These compounds may be useful as medicaments for the treatment of proliferative disorders as well as other diseases involving, relating to or associated with enzymes having histone deacetylase (HDAC) activities. | 02-19-2009 |
20090105302 | Macrocylic Inhibitors of Hepatitis C Virus - Inhibitors of HCV replication of formula (I) | 04-23-2009 |
20090105303 | SULFONYL-3-HETEROCYCLYLINDAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS - The present invention provides a compound of formula I and the use thereof for the treatment of a central nervous system disorder related to or affected by the 5-HT6 receptor. | 04-23-2009 |
20090124661 | HCV NS3 PROTEASE INHIBITORS - The present invention relates to macrocyclic compounds of formula (I) that are useful as inhibitors of the hepatitis C virus (HCV) NS3 protease, their synthesis, and their use for treating or preventing HCV infections. | 05-14-2009 |
20090137630 | SUBSTITUTED THIOPHENES: COMPOSITIONS, PROCESSES OF MAKING, AND USES IN DISEASE TREATMENT AND DIAGNOSIS - The present invention comprises compounds and compositions comprising substituted thiophene derivatives with the following backbone structure: | 05-28-2009 |
20090143434 | Methods of using domperidone to terminate acute episodes of cardiac arrhythmia, to restore normal sinus rhythm or heart rate, to prevent recurrence of cardiac arrhythmia and to maintain normal sinus rhythm or heart rate in mammals - Disclosed are methods of terminating acute episodes of cardiac arrhythmia, such as atrial fibrillation or ventricular fibrillation, in a mammal, such as a human, by administering to that mammal an amount of domperidone, or a pharmaceutically acceptable salt, derivative or metabolite thereof, effective to terminate an acute episode of cardiac arrhythmia and/or restore normal sinus rhythm or heart rate. Also disclosed are methods of maintaining normal sinus rhythm or heart rate in a mammal, such as a human, and preventing a recurrence of an episode of cardiac arrhythmia in a mammal, by administering an amount of domperidone, or a pharmaceutically acceptable salt, derivative or metabolite thereof, effective to maintain normal sinus rhythm or heart rate in a mammal that has experienced at least one prior episode of cardiac arrhythmia. Pharmaceutical compositions for use in these methods are also disclosed. | 06-04-2009 |
20090163547 | INDENE DERIVATIVES, THEIR PREPARATION AND USE AS MEDICAMENTS -
The present invention makes reference to new indene derivatives with general formula (I), as well as to their preparation procedures, their application as medicament and the pharmaceutical compositions containing them. The new compounds of formula (I) show affinity for 5-HT | 06-25-2009 |
20090176831 | Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System - Disclosed are compounds of the general formula (I): | 07-09-2009 |
20090215824 | INDAZOLE DERIVATIVES AS INHIBITORS OF HORMONE SENSITIVE LIPASE - The present invention relates to indazole derivatives of the general formulae I or II having the meanings indicated in the description, to the pharmaceutically useful salts thereof and the use thereof as drugs. | 08-27-2009 |
20090221641 | Diaza-spiro--nonane derivatives as neurokinin (nk1) antagonists - This invention concerns substituted diaza-spiro-[4.4]-nonane derivatives having neurokinin antagonistic activity, in particular NK1 antagonist ic activity, their preparation, compositions comprising them and their use as a medicine, in particular for the treatment and/or prophylaxis of schizophrenia, emesis, anxiety and depression, irritable bowel syndrome (IBS), circadian rhythm disturbances, pre-eclampsia, nocicept ion, pain, in particular visceral and neuropathic pain, pancreatitis, neurogenic inflammation, asthma, chronic obstructive pulmonary disease (COPD) and micturition disorders such as urinary incontinence. The compounds according to the invention can be represented by general Formula (I) and comprises also the pharmaceutically acceptable acid or base addition salts thereof, the stereochemically isomeric forms thereof, the N-oxide form thereof and prodrugs thereof, wherein all substituents are defined as in Claim | 09-03-2009 |
20090221642 | MUSCARINIC RECEPTOR AGONISTS, COMPOSITIONS, METHODS OF TREATMENT THEREOF, AND PROCESSES FOR PREPARATION THEREOF-176 - Compounds of Formula 1, or pharmaceutically acceptable salts thereof: | 09-03-2009 |
20090253747 | Remedy for sleep disturbance - The present invention has been made based on the finding that a compound acting on the ORL-1 receptor as an agonist acts as a non-photic entrainment factor, and advances the circadian rhythm phase, and provides a novel therapeutic agent for a sleep disorder such as circadian rhythm sleep disorder, more particularly, an agent for the prophylaxis and/or treatment of a sleep disorder, which contains an ORL-1 receptor agonist, and a novel compound useful as such agent for the prophylaxis and/or treatment. | 10-08-2009 |
20090264468 | Methods for treating a disease in which Rho kinase is involved - A method for treating a disease in which Rho kinase is involved. The method is carried out by administering to a patient in need thereof a pharmaceutically effective amount of a compound of the following formula or a pharmaceutically acceptable salt thereof: | 10-22-2009 |
20100004285 | POLYMORPH OF 4-[2-[4-[1-(2-ETHOXYETHYL)-1H-BENZIMIDAZOLE-2-YL]-1-PIPERIDINYL]ETHYL]-al- pha alpha-DIMETHYL-BENZENEACETIC ACID - Crystalline form 1 4-[2-[4-[1 -(2-ethoxyethyl)-1H-benzimidazole-2-yl]-1-piperidinyl]-ethyl]-αα-dimethyl-benzeneacetic acid of formula (I) is described, procedures for its preparation, pharmaceutical formulae containing crystalline form 1 and the use of crystalline form 1 to treat allergic reactions and pathological processes mediated by histamine in mammals such as man. | 01-07-2010 |
20100056573 | 2-ALKYL-INDAZOLE COMPOUNDS FOR THE TREATMENT OF CERTAIN CNS-RELATED DISORDERS - 2-Alkyl-indazole compound and its pharmaceutically acceptable salts of acid addition, method and intermediates for preparing them, a pharmaceutical composition containing them and use of the latter. The 2-alkyl-indazole compound has the following general formula (I) in which R1, R2, R3, R4, R6, R7, X, Y, W, n, p, and m have the meanings stated in the description. | 03-04-2010 |
20100113519 | 1,5-Dideoxy-1,5-imino-D-glucitol Compounds - 1,5-Dideoxy-1,5-imino-D-glucitol compounds as shown in the specification. Also disclosed is a method of treating a hexosaminidase-associated disease. | 05-06-2010 |
20100173941 | Muscarinic Receptor Agonists that are Effective in the Treatment of Pain, Alzheimer's Disease and Schizophrenia - Compounds of Formulae I, or pharmaceutically acceptable salts thereof: wherein R | 07-08-2010 |
20100179190 | BICYCLIC PYRAZOLO PROTEIN KINASE MODULATORS - The present invention provides novel bicyclic pyrazolo kinase modulators and methods of using the novel bicyclic pyrazolo kinase modulators to treat diseases mediated by kinase activity. | 07-15-2010 |
20100190825 | BENZIMIDAZOLES WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE - Compounds of formula (I) and salts and solvates are provided: | 07-29-2010 |
20100190826 | BENZIMIDAZOLE DERIVATIVE - Provided is a novel and excellent method for treating and/or preventing benign prostatic hyperplasia, prostate cancer, and the like based on selective inhibitory activity against 17βHSD type 5. It was found that an indole or benzimidazole derivative, where a nitrogen atom of the indole ring or benzimidazole ring is substituted with a phenyl group substituted with COOH, has a potent selective inhibitory activity against 17βHSD type 5 and may become an agent for treating and/or an agent for preventing a disease associated with 17βHSD type 5, such as benign prostatic hyperplasia, prostate cancer and the like, without accompanying adverse effects due to a decrease in testosterone; and the present invention has thus been completed. | 07-29-2010 |
20100197733 | PYRROLIDINES AND PIPERIDINES AS OREXIN RECEPTOR ANTAGONISTS - The invention relates to compounds of formula (I) wherein Y, A, N and R | 08-05-2010 |
20100234425 | 2-SUBSTITUTED-1H-BENZIMIDAZOLE-4-CARBOXAMIDES ARE PARP INHIBITORS - Compounds of Formula (I) | 09-16-2010 |
20100240702 | Benzimidazolone Chymase Inhibitors - Disclosed are small molecule inhibitors which are useful in treating various diseases and conditions involving chymase. | 09-23-2010 |
20100280071 | BENZIMIDAZOLES WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE - Compounds of formula (I), salts and solvates are provided: | 11-04-2010 |
20100286202 | New Compounds - The present invention relates to new compounds | 11-11-2010 |
20100286203 | PHARMACEUTICALLY ACCEPTABLE SALTS OF 2--2H-INDAZOLE-7-CARBOXAMIDE - The present invention relates to pharmaceutically acceptable salts of an amide substituted indazole which are inhibitors of the enzyme poly(ADP-ribose)polymerase (PARP), previously known as poly(ADP-ribose)synthase and poly(ADP-ribosyl) transferase. The compounds of the present invention are useful as mono-therapies in tumors with specific defects in DNA-repair pathways and as enhancers of certain DNA-damaging agents such as anticancer agents and radiotherapy. Further, the compounds of the present invention are useful for reducing cell necrosis (in stroke and myocardial infarction), down regulating inflammation and tissue injury, treating retroviral infections and protecting against the toxicity of chemotherapy. | 11-11-2010 |
20100298380 | N-ARYL-N-PIPERIDIN-4-YLMETHYL-AMIDE DERIVATIVES AND THIER USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS - This invention relates to novel N-aryl-N-piperidin-4-ylmethyl amide derivatives useful as monoamine neurotransmitter re-uptake inhibitors. | 11-25-2010 |
20110034512 | Indazole Compounds As CCR1 Receptor Antagonists - Disclosed indazoles compounds that are useful as antagonists of CCR1 activity and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of CCR1 including autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis. Also disclosed are pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes. | 02-10-2011 |
20110039891 | Methods for treating a disease in which Rho kinase is involved - A method for treating a disease in which Rho kinase is involved. The method is carried out by administering to a patient in need thereof a pharmaceutically effective amount of a compound of the following formula or a pharmaceutically acceptable salt thereof: | 02-17-2011 |
20110166181 | GUANIDINE COMPOUNDS AS ANESTHETICS AND FOR TREATMENT OF NERVOUS SYSTEM DISORDERS - Novel guanidine compounds having the formula | 07-07-2011 |
20110178128 | BENZIMIDAZOLE COMPOUND IN CRYSTAL FORM AND SALT THEREOF - The present invention aims to provide a stable form of (R)-2-{3-[1-(acenaphthen-1-yl)piperidin-4-yl]-2,3-dihydro-2-oxo-benzimidazol-1-yl}-N-methylacetamide, which is free of problems of water adsorption and the like, and shows superior water solubility. | 07-21-2011 |
20110207777 | BENZIMIDAZOLES WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE - Compounds of formula (I), salts and solvates are provided, | 08-25-2011 |
20110237624 | INDAZOLES, BENZISOXAZOLES AND BENZISOTHIAZOLES AND THEIR USE AS ESTROGENIC AGENTS - The present invention relates to compounds of formula (I): | 09-29-2011 |
20110263648 | BRIDGED TETRAHYDRONAPHTHALENE DERIVATIVES - The invention relates to compounds of formula (I) wherein R | 10-27-2011 |
20110306638 | BENZISOXAZOLE PIPERIDINYL DERIVATIVES, PHARMACEUTICAL COMPOSITIONS COMPRISING THE DERIVATIVES AND THEIR USE - The invention relates to a benzisoxazolyl piperidine derivative having the following general formula, a salt or a hydrate thereof, | 12-15-2011 |
20120041027 | BENZIMIDAZOLES WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE - Compounds of formula (I) and salts and solvates are provided: | 02-16-2012 |
20120041028 | BENZIMIDAZOLES WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE - Compounds of formula (I), salts and solvates are provided: | 02-16-2012 |
20120157495 | BENZIMIDAZOLE DERIVATIVES - The present invention relates to a compound of the Formula I | 06-21-2012 |
20120196896 | Treatment for Oxidative Stress and/or Hypertension - One aspect of the invention relates to compounds, compositions and methods for treating oxidative stress and/or hypertension. In certain embodiments, the invention relates to a mixture of tempol and an angiotensin receptor blocker (ARB) and the use of said mixture to treat oxidative stress and/or hypertension. In certain embodiments, the invention relates to a tempol/ARB adduct and the use of said adduct to treat oxidative stress and/or hypertension. | 08-02-2012 |
20120196897 | NEW COMPOUNDS - The present invention relates to compounds of general formula I | 08-02-2012 |
20120232112 | AMINO-SUBSTITUTED 3-HETEROAROYLAMINO-PROPIONIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS - The present invention relates to compounds of the formula I, | 09-13-2012 |
20120252843 | ISOINDOLINE COMPOUNDS AND METHODS OF THEIR USE - Provided herein are isoindoline compounds, pharmaceutical compositions comprising one or more of such compounds, and methods of their use for treating, preventing, or managing various diseases. | 10-04-2012 |
20120302604 | Modulation of Phospholipase D for the Treatment of the Acute and Chronic Effects of Ethanol - The present invention relates to methods of decreasing the negative effects of alcohol on behavior as well as inhibiting the toxic effects of alcohol, comprising administering, to a subject, an effective amount of an inhibitor of phospholipase D. | 11-29-2012 |
20120309789 | Compounds which have activity at M1 receptor and their uses in medicine - Compounds of general formula | 12-06-2012 |
20120316202 | Compounds which have activity at M1 receptor and their uses in medicine - Compounds of the general formula | 12-13-2012 |
20120322826 | 5-HT4 RECEPTOR AGONISTS FOR THE TREATMENT OF DEMENTIA - This invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof with 5-HT4 agonistic activities, which is useful in the treatment of dementia. This invention also relates to a pharmaceutical composition for the treatment of dementia which comprises a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof. Further this invention relates to a method for the treatment of dementia in an animal subject including a mammalian subject, which comprises administering to the animal subject including a mammalian subject a compound of the formula (I) or a pharmaceutically acceptable salt thereof. | 12-20-2012 |
20130012543 | CYTOSKELETAL ACTIVE RHO KINASE INHIBITOR COMPOUNDS, COMPOSITION AND USE - The present invention is directed to synthetic cytoskeletal active compounds that are inhibitors of rho-associated protein kinase. The present invention is also directed to pharmaceutical compositions comprising such compounds and a pharmaceutically acceptable carrier. The invention is additionally directed to a method of preventing or treating diseases or conditions associated with cytoskeletal reorganization. In one embodiment of the invention, the method treats increased intraocular pressure, such as primary open-angle glaucoma. The method comprises administering to a subject a therapeutically effective amount of a cytoskeletal active compound of Formula I or Formula II, wherein said amount is effective to influence the actomyosin interactions, for example by leading to cellular relaxation and alterations in cell-substratum adhesions. | 01-10-2013 |
20130116284 | LIPOIC ACID AND NITROXIDE DERIVATIVES AND USES THEREOF - Provided are bifunctional compounds comprising a poly(ADP-ribose) polymerase (PARP) inhibitor moiety and a reactive oxygen species (ROS) scavenger moiety, more particularly, a lipoic acid or cyclic nitroxide derivative, covalently attached either directly or via a linker, as well as pharmaceutical compositions comprising them. The compounds and pharmaceutical compositions are useful for prevention, treatment, or management of diseases, disorders and conditions associated with elevated PARP activity or expression. | 05-09-2013 |
20130303571 | NEW COMPOUNDS - The present invention relates to compounds of general formula I | 11-14-2013 |
20140080868 | Methods for Treating HCV - Pan-genotypic HCV inhibitors are described. This invention also relates to methods of using these inhibitors to treat HCV infection. | 03-20-2014 |
20140080869 | Methods for Treating HCV - Pan-genotypic HCV inhibitors are described. This invention also relates to methods of using these inhibitors to treat HCV infection. | 03-20-2014 |
20140121243 | NOVEL 1-SUBSTITUTED INDAZOLE DERIVATIVE - A medicament for treating diseases associated with cholinergic properties in the central nervous system (CNS) and/or peripheral nervous system (PNS), diseases associated with smooth muscle contraction, endocrine disorders, neurodegenerative disorders and the like, which comprises a compound of Formula (I): | 05-01-2014 |
20140121244 | NOVEL 1-SUBSTITUTED INDAZOLE DERIVATIVE - A medicament for treating diseases associated with cholinergic properties in the central nervous system (CNS) and/or peripheral nervous system (PNS), diseases associated with smooth muscle contraction, endocrine disorders, neurodegenerative disorders and the like, which comprises a compound of Formula (I): | 05-01-2014 |
20140235675 | 3-OXO-2,3-DIHYDRO-1H-INDAZOLE-4-CARBOXAMIDE DERIVATIVES AS PARP-1 INHIBITORS - There are provided 3-oxo-2,3-dihydro-1H-indazole-4-carboxamide derivatives which selectively inhibit the activity of poly (ADP-ribose) polymerase PARP-1 with respect to poly (ADP-ribose) polymerase PARP-2. The compounds of this invention are therefore useful in treating diseases such as cancer, cardiovascular diseases, central nervous system injury and different forms of inflammation. The present invention also provides methods for preparing these compounds, pharmaceutical compositions comprising these compounds, and methods of treating diseases utilizing pharmaceutical compositions comprising these compounds. | 08-21-2014 |
20140249183 | Treatment for Substance Use Disorders and Stress Disorders - Treatments are described for stress disorders and substance use disorders, for example, substance use disorders associated with use of alcohol, cocaine, amphetamines, and the like. | 09-04-2014 |
20140275167 | HEPATITIS B ANTIVIRAL AGENTS - Provided herein are compounds useful for the treatment of HBV infection in man. | 09-18-2014 |
20140329858 | Cyclic Urea Derivatives As Androgen Receptor Antagonists - The present invention is directed to compounds of formula (I) wherein R | 11-06-2014 |
20140350052 | Methods and Compositions for Reducing Serum Levels of Immunoglobulin E (IGE) - The present disclosure provides methods and pharmaceutical compositions for reducing the serum level of immunoglobulin IgE in an animal or human subject. It has been found that reducing or inhibiting the activity of the cannabinoid receptor CB2 leads to an increase in IgE in serum levels. Conversely, activation of the CB2 receptor by an agonist results in a reduction in IgE serum levels. The compositions and methods of the disclosure, therefore, provide a means to reduce or eliminate symptoms of immune system-related conditions resulting from IgE generation, such as an allergy, hay fever, and the like. | 11-27-2014 |
20150051248 | IMIDAZOLYL METHYL PIPERIDINE T-TYPE CALCIUM CHANNEL ANTAGONISTS - The present invention is directed to imidazolyl methyl piperidine compounds which are antagonists of T-type calcium channels, and which are useful in the treatment or prevention of disorders and diseases in which T-type calcium channels are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which T-type calcium channels are involved. | 02-19-2015 |
20150126553 | BICYCLIC HETEROCYCLES CAPABLE OF MODULATING T-CELL RESPONSES, AND METHODS OF USING SAME - The present disclosure is directed in part to bicyclic heterocycles, such as a compound represented by formula (I) or (II) as disclosed herein, and their use in treating medical disorders, such as immune inflammatory disorders such as Crohn's disease, ulcerative colitis, rheumatic disorders, psoriasis, and allergies. The compounds are contemplated to modulate T-Cell responses. | 05-07-2015 |
20150133500 | BENZIMIDAZOLE DERIVATIVES AND USE THEREOF - The invention provides compounds that are useful as sodium channel blockers. In one aspect, the invention provides compounds of Formula I: | 05-14-2015 |
20160090373 | SOLID FORMS OF ANTI-VIRAL COMPOUNDS - Disclosed are crystalline forms of a compound of formula (I), methods of their preparation, and related pharmaceutical preparations thereof. | 03-31-2016 |
20160152567 | NOVEL ALLOSTERIC INHIBITORS OF PROTEASOME AND METHODS OF USE THEREOF | 06-02-2016 |
20160160294 | METHODS AND MATERIALS FOR PREDICTING RESPONSE TO NIRAPARIB - This document provides methods and materials involved in assessing samples (e.g., cancer cells) for the presence of homologous recombination deficiency (HRD) or an HRD signature to predict response to niraparib. For example, methods and materials for determining whether or not a cell (e.g., a cancer cell) contains an HRD signature to predict response to niraparib are provided. | 06-09-2016 |
20170233354 | FLT3 RECEPTOR ANTAGONISTS | 08-17-2017 |